|
|
|
|
|
|
|
|
|
|
|
|
|
| Dockets Entered
On July 11, 2006
|
|
|
|
|
|
|
| Docket #
|
| Title
|
|
|
|
|
| 1978N-0038
|
| Sunscreen Drug Products
|
|
|
| 2001D-0220
|
| Biological Prod Deviation
Reporting for Blood & Plasma Estab
|
|
|
| 2003P-0176
|
| Follow-On Approval
of Therapeutic Protein Products
|
|
|
| 2004E-0393
|
| Patent Extension for
Uroxatral (Alfuzosin hydrochloride), U.S. Patent No. 4,661,491
|
|
|
| 2004N-0355
|
| Scientific Considerations
Related to Developing Follow-on Protein Products
|
|
|
| 2004P-0171
|
| Standards for 'Similarity'
or 'Sameness' of Biotechnology-Derived Products
|
|
|
| 2004P-0231
|
| Deny approval of NDA
21-426 for Ominitrop 5.8 mg somatropin [ rDNA origin ] for injection,
lyophilized powder and diluent with preservative
|
|
|
| 2004P-0329
|
| Request Public Hearings
regarding the sales, distribution and use of hand-held Doppler fetoscopes
|
|
|
| 2005D-0122
|
| Guidance for Industry
on Exploratory IND Studies
|
|
|
| 2005D-0385
|
| Guidance for Industry
on Using Electronic Means to Distribute Certain Product Information
|
|
|
| 2005E-0236
|
| Patent Extension Application
for MULTIHANCE (gadobenate dimeglumine), U.S. Patent No. 4,916,246
|
|
|
| 2005N-0437
|
| Medical Gas Containers
and Closures; Current Good Manufacturing
|
|
|
| 2005P-0411
|
| Seeking FDA Actions
to Counter Flagrant Violations of the Law by Pharmacies Compounding
Bio-Identical Hormone Replacement Therapy Drugs
|
|
|
| 2006D-0099
|
| Class II Special Controls
Guidance Document: Reagents for Detection of Specific Novel Influenza
A Viruses
|
|
|
| 2006D-0121
|
| Guidance for Industry
and Food and Drug Administration: In Vitro Diagnostic Devices to Detect
Influenza A Viruses: Labeling and Regulatory Path
|
|
|
| 2006D-0172
|
| Guidance
for Clinical Investigators, Institutional Review Boards and Sponsors
Process for Handling Referrals to FDA Under 21 CFR 50.54 : Additional
Safeguards for Children in Clinical Investigations
|
|
|
|
|
|
| 2006D-0226
|
| Prescription Drug
Marketing Act Pedigree Requirements under 21 CFR Part 203; Effective
Date and Compliance Policy GuideProgram, Draft Guidance; Availability
|
|
|
| 2006E-0025
|
| Patent Extension Application
for INCRELEX (mecasermin rDNA orgin injection), U.S. Patent No. 5,681,814
|
|
|
| 2006N-0181
|
| Product Stability
Data: Notice of Pilot Project
|
|
|
| 2006O-0232
|
| Over-the-Counter Drug
Products; Safety and Efficacy Review; Additional Laxative Ingredient
|
|
|
| 2006P-0151
|
| Stay the current approvable
letter with conditions of any and all Premarket Applications for silicone
gel-filled breast implants
|
|
|
| 2006P-0210
|
| Amend regulations
for products composed of engineered nanoparticles generally and sunscreen
drug products composed of engineered nanoparticles specifically
|
|
|
| 2006P-0218
|
| To permit an abbrevation
New Drug Application Triamcinolone Diacetate Suspension
|
|
|
| 2006P-0245
|
| Exclusivity Determination
for Risperidone
|
|
|
| 1978N-0038
|
| Sunscreen Drug
Products
|
|
|
| SUP 35
|
| International Center
for Technology Assessment (CTA)
|
| Vol #:
|
| 150
|
|
|
| 2001D-0220
|
| Biological Prod
Deviation Reporting for Blood & Plasma Estab
|
|
|
| C 10
|
| Plasma Protein Therapeutics
Association (PPTA)
|
| Vol #:
|
| 1
|
|
|
| 2003P-0176
|
| Follow-On Approval
of Therapeutic Protein Products
|
|
|
| REF 1
|
| References for Citizen
Petition Response
|
| Vol #:
|
| 4
|
|
|
| 2004E-0393
|
| Patent Extension
for Uroxatral (Alfuzosin hydrochloride), U.S. Patent No. 4,661,491
|
|
|
| C 1
|
| D. Lowe
|
| Vol #:
|
| 1
|
|
|
| 2004N-0355
|
| Scientific Considerations
Related to Developing Follow-on Protein Products
|
|
|
|
|
|
|
|
|
|
|
|
|
| REF 1
|
| References for Citizen Petition
Response
|
| Vol #:
|
| 21
|
|
|
| 2004P-0171
|
| Standards for 'Similarity'
or 'Sameness' of Biotechnology-Derived Products
|
|
|
| REF 1
|
| References for Citizen Peition
Response
|
| Vol #:
|
| 4
|
|
|
| 2004P-0231
|
| Deny approval of
NDA 21-426 for Ominitrop 5.8 mg somatropin [ rDNA origin ] for injection,
lyophilized powder and diluent with preservative
|
|
|
| REF 1
|
| References for Citizen Peition
Response
|
| Vol #:
|
| 5
|
|
|
| 2004P-0329
|
| Request Public
Hearings regarding the sales, distribution and use of hand-held Doppler
fetoscopes
|
|
|
| PDN 1
|
| FDA/CDRH to Russel J. Thomsen,
M.D.
|
| Vol #:
|
| 3
|
|
|
| 2005D-0122
|
| Guidance for Industry
on Exploratory IND Studies
|
|
|
| EC 18
|
| Mr. Dave Lowe
|
| Vol #:
|
| 2
|
|
|
| 2005D-0385
|
| Guidance for Industry
on Using Electronic Means to Distribute Certain Product Information
|
|
|
| EC 13
|
| Mr. Dave Lowe
|
| Vol #:
|
| 1
|
|
|
| 2005E-0236
|
| Patent Extension
Application for MULTIHANCE (gadobenate dimeglumine), U.S. Patent No.
4,916,246
|
|
|
| N 1
|
| FDA
|
| Vol #:
|
| 1
|
|
|
| 2005N-0437
|
| Medical Gas Containers
and Closures; Current Good Manufacturing
|
|
|
| C 8
|
| Great Plains Homecare Equipement
|
| Vol #:
|
| 1
|
|
|
| C 9
|
| Barlen and Associates, Inc.
|
| Vol #:
|
| 1
|
|
|
| C 10
|
| Depke Gases & Welding Supplies,
Inc.
|
| Vol #:
|
| 1
|
|
|
| C 11
|
| Compressed Gas Association (CGA)
and Gases and Welding Distributors Association (GAWDA)
|
| Vol #:
|
| 1
|
|
|
| C 12
|
| Four Corners Welding & Gas
Supply (FCWGS)
|
| Vol #:
|
| 1
|
|
|
| C 13
|
| Albright Welding Supply Co.,
Inc.
|
| Vol #:
|
| 1
|
|
|
| C 14
|
| Prest-O-Sales & Service,
Inc.
|
| Vol #:
|
| 1
|
|
|
| C 15
|
| General Distributing, Co.
|
| Vol #:
|
| 1
|
|
|
| C 16
|
| Buffalo Welding Supply Co.,
Inc.
|
| Vol #:
|
| 1
|
|
|
| C 17
|
| DeVille Oxygen
|
| Vol #:
|
| 1
|
|
|
| C 18
|
| DJB Gas Services, Inc.
|
| Vol #:
|
| 1
|
|
|
| C 19
|
| Oxarc, Inc.
|
| Vol #:
|
| 1
|
|
|
| C 20
|
| TexAir Welding Supply, Ltd
|
| Vol #:
|
| 1
|
|
|
| C 21
|
| Oxarc, Inc.
|
| Vol #:
|
| 1
|
|
|
| C 22
|
| Myco Supply
|
| Vol #:
|
| 1
|
|
|
| C 23
|
| Oxarc, Inc.
|
| Vol #:
|
| 1
|
|
|
| C 24
|
| Scott-Gross Company, Inc.
|
| Vol #:
|
| 1
|
|
|
| C 25
|
| Bemidji Welders Supply
|
| Vol #:
|
| 1
|
|
|
|
|
|
|
|
|
|
|
|
|
| Clinical Investigations
|
|
|
| EC 2
|
| Pharm Res
|
| Vol #:
|
| 1
|
|
|
| 2006D-0226
|
| Prescription Drug
Marketing Act Pedigree Requirements under 21 CFR Part 203; Effective
Date and Compliance Policy GuideProgram, Draft Guidance; Availability
|
|
|
| C 1
|
| D. Lowe
|
| Vol #:
|
| 1
|
|
|
| 2006E-0025
|
| Patent Extension
Application for INCRELEX (mecasermin rDNA orgin injection), U.S. Patent
No. 5,681,814
|
|
|
| C 1
|
| D. Lowe
|
| Vol #:
|
| 1
|
|
|
| 2006N-0181
|
| Product Stability
Data: Notice of Pilot Project
|
|
|
| EC 4
|
| Fort Dodge Animal Health
|
| Vol #:
|
| 1
|
|
|
| EC 5
|
| ActivBiotics Inc.
|
| Vol #:
|
| 1
|
|
|
| 2006O-0232
|
| Over-the-Counter
Drug Products; Safety and Efficacy Review; Additional Laxative Ingredient
|
|
|
| BKG 1
|
| Background Information
|
| Vol #:
|
| 1
|
|
|
| 2006P-0151
|
| Stay the current
approvable letter with conditions of any and all Premarket Applications
for silicone gel-filled breast implants
|
|
|
| EC 614
|
| Univ. Mass Medical School
|
| Vol #:
|
| 3
|
|
|
| EC 615
|
| Ms. Myrl Jeffcoat
|
| Vol #:
|
| 3
|
|
|
| EC 616
|
| Mrs. Cindy Fuchs-Morrissey
|
| Vol #:
|
| 3
|
|
|
| EC 617
|
| Ms. Beth Taylor
|
| Vol #:
|
| 3
|
|
|
| EC 618
|
| Mrs. Debbie Riffel
|
| Vol #:
|
| 3
|
|
|
| 2006P-0210
|
| Amend regulations
for products composed of engineered nanoparticles generally and sunscreen
drug products composed of engineered nanoparticles specifically
|
|
|
| SUP 2
|
| International Center for Technology
Assessment (CTA)
|
| Vol #:
|
| 3
|
|
|
| 2006P-0218
|
| To permit an abbrevation
New Drug Application Triamcinolone Diacetate Suspension
|
|
|
| C 1
|
| D. Lowe
|
| Vol #:
|
| 1
|
|
|
| 2006P-0245
|
| Exclusivity Determination
for Risperidone
|
|
|
| EC 9
|
| Mr. Dave Lowe
|
| Vol #:
|
| 1
|
|